

## **General Guidelines**

- 1. All abstracts must be written in English.
- 2. It should be typed single spaced, in Times New Romans with font size 12.
- 3. Title should be typed bold in capital letters.
- 4. The abstract title should not exceed 14 words.
- 5. The number of authors per abstract is unlimited.
- 6. The authorship should indicate institutional affiliation.
- 7. Corresponding author should provide e-mail address and postal address
- 8. The presenting author's name (for both oral and poster presentation) should be underlined.
- 9. The abstract text should not exceed 250 words.
- 10. Abstracts should be formulated under the headings of background, methods, results/findings, conclusions and key words.
- 11. It is the author's responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as typed by the author.
- 12. Tables and graphs should not be included.
- 13. The selection of an abstract whether oral or poster is at the discretion of Scientific Committee. The approval of abstracts will be intimated through e-mails for confirmation well ahead of time so that participants have enough time for preparation.

If you have any questions regarding your abstract submission, please contact <a href="mailto:lubna.amin@aku.edu">lubna.amin@aku.edu</a>

# **Choosing Abstract Track Categories**

The abstract track category is the general heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. Please choose the category which **best** describes the subject of your abstract.

- a. Blood banking & Transfusion Medicine
- b. Thrombosis & haemostasis
- c. Laboratory Haematology / Quality Assurance
- d. Malignant Haematology
- e. Benign Haematology

## Dead line for submission: March 15, 2016

We encourage studies that introduce new ideas and conceptualizations, research and understanding to the field.

Please note that all incomplete abstracts including those mentioning 'study in progress and results will be presented in the conference' are liable to be rejected.





#### **Abstract Format**

**Background:** briefly indicate the problem statement and research question/objective(s) of the study. Objective should be clear and concise.

**Methods:** describe the study setting, design, and study population, sample size/recruitment of study participants, data collection tools and methods of analysis.

**Results/findings:** present as clearly and detailed as possible the results/findings of the study, with specific results in summarized form.

**Conclusions:** briefly discuss the data and main outcome of the study. Emphasize the future implications of the results and policy relevance.

**Key words:** 3-5 key words should be provided.

Is this study approved /exempted from Institutional Ethical Review Committee or Institutional Review Board or equivalent: Yes No

If yes, please ethical committee approval/exemption number

### **Abstract Transparency Policy**

An abstract can be submitted and may be accepted although it has been previously published or presented at a national, regional or international meeting, **provided** that there are new methods, new findings, updated information or other valid reasons for submitting that can be provided by the author.

If preliminary or partial data has been published or presented, the author is required to indicate the details of that conference, meeting or journal and the reasons for submitting the abstract to this conference. This information will be considered by the Scientific Programme Committee when making final decisions.

#### **Ethical Research Declaration**

The conference supports only research that has been conducted according to the protocol approved by the institutional or local committee on ethics in human investigation. Where no such committee exists, the research should have been conducted in accordance with the principles of the Declaration of Helsinki of World Medical Association.

# Notification of Acceptance or Rejection to Corresponding Author

Notification of acceptance or rejection will be sent to the submitting (corresponding) author. Please note that **only** the corresponding author will receive mail concerning the abstract and is responsible for informing all co-authors of the status of the abstract. Authors whose abstracts have been accepted will receive instructions for the presentation of their abstract. The decision of the Scientific Programme Committee is final and appeals will not be considered.